Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1

Anna Tosi, Silvia Dalla Santa, Elisa Cappuzzello, Carolina Marotta, Dawid Walerich, Giannino Del Sal, Paola Zanovello, Roberta Sommaggio, and Antonio Rosato

Introduction

In recent years, the field of cancer immunotherapy has considerably expanded with the introduction of several new treatment options, including cancer vaccines, adoptive cell transfer, chimeric-antigen receptor (CAR) T-cell therapy, monoclonal antibodies and immune checkpoint inhibitors (ICI).1 Although some patients with advanced cancer may respond to single-agent immunotherapy, for the majority, however, monotherapy is relatively ineffective.2 Hence, multiple combined therapeutic approaches are likely required to achieve complete remission and cure.

As tumors grow, they accumulate mutations leading to potential generation of neoantigens that influence the response of patients to ICI. Indeed, T cells recognizing clonal neoantigens were detected in non-small cell lung cancer and melanoma patients with durable clinical benefits after therapy with anti-PD-1 and anti-CTLA-4 blockades, suggesting that therapy with ICI enhances neoantigen-specific T-cell reactivity.3-5 Accordingly, the combination therapy of ICI with cancer vaccines or the adoptive transfer of enriched populations of neoantigen-reactive T cells may function synergistically to induce more effective antitumor immune responses.6 For example, in patients not responding to ICI because of the lack of tumor-infiltrating lymphocytes, cancer vaccines may induce effector T-cell infiltration into the tumors.7 These findings support therapeutic developments targeting clonal neoantigens to design personalized immunotherapies to treat patients with advanced cancer.

Despite this evidence, the identification of expressed nonsynonymous somatic mutations by whole-exome sequencing of tumor and normal DNA, which allows the selection of candidate neoepitopes to be exploited for developing personalized immunotherapies, is typically unwieldy, time-consuming and expensive.8 To overcome the practical limitations of...
personalized cancer immunotherapy, the identification of universal tumor-specific antigens (TSA) shared between multiple patients and/or multiple tumors has been gaining renewed interest and great importance. Furthermore, the selection of TSAs playing a key role in tumor cell proliferation and survival is considered crucial to overcome immune escape, as their downregulation or loss is expected to impair tumor progression.9 In this regard, encouraging results have been achieved in triple negative breast cancer (TNBC), an aggressive form of neoplasia that occurs in approximately 15% of all breast cancer patients23 and still lacks proper therapeutic solutions. Together with a leading role in tumorigenesis, the broad and cancerspecific expression of DEPDC1 suggests that it might be regarded as a novel universal oncoantigen potentially suitable for targeting many different cancers. In this regard, we also report the identification of an immunogenic DEPDC1-derived epitope restricted to the HLA-A*0201 molecule, which can foster a strong and specific CTL response in vitro. Such CTLs recognize the endogenously processed and presented DEPDC1-derived peptide on tumor cells, and are therapeutically active against human TNBC xenografts in vivo upon adoptive transfer. Thus, this DEPDC1-derived antigenic epitope can represent a new tool for the development of immunotherapeutic strategies for HLA-A*0201 patients with TNBC, and potentially many other cancers.

Results

**DEPDC1 is widely expressed in tumors but not in normal tissues**

The Oncomine database was interrogated for DEPDC1 gene expression.24,25 Fourteen independent data sets referred to

Based on these observations, the clinical exploitation of **DEPDC1** as an immunological target for vaccination in HLA-A*2402 subjects has started both in bladder cancer patients,20,21 and patients with gastrointestinal, lung or cervical tumors,22 with promising results.

Here, we report that DEPDC1 expression is upregulated in most types of human tumors, and particularly well represented in triple negative breast cancer (TNBC), an aggressive form of neoplasia that occurs in approximately 15% of all breast cancer patients23 and still lacks proper therapeutic solutions. Together with a leading role in tumorigenesis, the broad and cancerspecific expression of **DEPDC1** suggests that it might be regarded as a novel universal oncoantigen potentially suitable for targeting many different cancers. In this regard, we also report the identification of an immunogenic DEPDC1-derived epitope restricted to the HLA-A*0201 molecule, which can foster a strong and specific CTL response in vitro. Such CTLs recognize the endogenously processed and presented DEPDC1-derived peptide on tumor cells, and are therapeutically active against human TNBC xenografts in vivo upon adoptive transfer. Thus, this DEPDC1-derived antigenic epitope can represent a new tool for the development of immunotherapeutic strategies for HLA-A*0201 patients with TNBC, and potentially many other cancers.

Figure 1. DEPDC1 is upregulated in different human cancers. (A) DEPDC1 mRNA expression in normal (white) and tumor tissues (gray) as reported from microarray studies in the Oncomine database. Breast: (t-test = 10.953; p-value = 1.18E−14);28 bladder (t-test = 6.217; p-value = 8.82E−9);29 brain (t-test = 9.929; p-value = 7.56E−12);26 cervix (t-test = 7.688; p-value = 9.13E−9);25 colon (t-test = 3.978; p-value = 9.98E−5);30 esophagus (t-test = 10.994; p-value = 8.17E−19);31 stomach (t-test = 7.379; p-value = 4.54E−10);32 nasopharynx (t-test = 5.832; p-value = 1.71E−6);33 leukemia (t-test = 4.400; p-value = 8.57E−4);34 liver (t-test = 6.180; p-value = 2.18E−7);35 lung (t-test = 16.310; p-value = 7.19E−18);36 skin (t-test = 5.874; p-value = 3.54E−5);37 ovary (t-test = 14.643; p-value = 2.12E−7) (TCGA Ovarian, No Associated Paper, 2013); pancreas (t-test = 4.794; p-value = 8.57E−6).36 Numbers above each box plot refer to the number of samples reported. (B) Endogenous expression of DEPDC1 protein in several human tumor cell lines (left panels) and in different normal human tissues (right panels), as assessed by western blot analysis. MDA-MB-231shDEPDC1 refers to cells with DEPDC1 silenced by shRNA, and served as an internal negative control.
different tumor histotypes showed an upregulation of DEPDC1 mRNA levels in primary cancers, as compared with normal counterpart tissues \( (p = 2.15E^{-7}) \), (Fig. 1A). Moreover, \textit{DEPDC1} expression turned out to be associated with pathologic and prognostic parameters independently from tumor type. Indeed, advanced stage (Table S1) and high-grade tumors (Table S2) overexpressed DEPDC1 mRNA as compared with early stage or low-grade tumors, respectively. Additionally, higher DEPDC1 mRNA levels were detected in primary tumor tissues from patients with metastatic events than in patients with no recurrence, and were related to a worst overall survival (Table S3). Noteworthy, 13 independent data sets of human TNBC showed overexpression of DEPDC1 compared with other breast cancer histotypes (Table S4).

Consistent with these findings, DEPDC1 protein was found to be expressed in a large set of human tumor cell lines of different histotypes, such as breast, bladder, brain, cervix, colon, stomach, leukemia, liver, lung and melanoma cell lines (Fig. 1B), thus supporting the concept that DEPDC1 can be regarded as a potential universal tumor-associated antigen, whose expression is strictly linked to the neoplastic status. Conversely, DEPDC1 was not found to be expressed in a set of normal different human tissues (bladder, breast, cervix, kidney, ovary, placenta, prostate and uterus; Fig. 1B), consistent with data reported by Kanehira et al.\textsuperscript{13} We failed, however, to visualize DEPDC1 protein in tissues, even though its specific mRNA had been previously detected by Northern blot, albeit at low levels.\textsuperscript{13}

### Table 1. Candidate peptides derived from DEPDC1 sequence, their predicted binding affinities to HLA-A’0201 and stabilization ratios.

| Peptide    | Start position | Peptide sequence | BIMAS score | NetMHC affinity (nm) | NetCTL score | Stabilization ratio on T2 cells |
|------------|----------------|------------------|-------------|---------------------|--------------|-------------------------------|
| DEPDC1#1   | 673            | FLMDHQOEI        | 728.022     | 6.05                | 1.4641       | 3.7                           |
| DEPDC1#2   | 580            | SMGTVQSL         | 57.085      | 20.15               | 1.2956       | 2.6                           |
| DEPDC1#3   | 588            | LLGLPHEL         | 133.255     | 47.31               | 1.2127       | 2.5                           |
| DEPDC1#4   | 574            | SLPSASSML        | 79.041      | 37.72               | 1.1822       | 2.5                           |
| DEPDC1#5   | 282            | FLDPEPPL         | 39.307      | 21.60               | 1.1503       | 2.9                           |
| DEPDC1#6   | 289            | LLTEFYYEL        | 54.474      | 41.23               | 1.1172       | 2.3                           |
| DEPDC1#7   | 524            | YINTPAEEL        | 165.46      | 165.46              | 1.2034       | 2.0                           |
| DEPDC1#8   | 786            | ALGFDQPKT        | 38.601      | 83.19               | 1.0145       | 1.3                           |
| DEPDC1#9   | 618            | LLMRMISR        | 71.872      | 58.86               | 1.0108       | 2.1                           |
| DEPDC1#10  | 562            | RLCKSTIEL        | 21.362      | 127.36              | 0.9906       | 1.2                           |

\textbf{In silico prediction of HLA-A’0201-restricted DEPDC1-derived peptides and assessment of their MHC stabilizing properties}

DEPDC1 amino acid (aa) sequence was analyzed for potential HLA-A’0201-restricted peptides using three epitope prediction algorithms available online, namely BIMAS, NetMHC and NetCTL. Different nine-aa peptides were classified according to their predicted ability to stabilize the MHC allele. The 10 peptides with the highest prediction score were chosen and synthesized for further studies (Table 1). To evaluate their ability to stabilize the HLA-A’0201 allele, the DEPDC1-derived peptides were incubated with antigen-processing deficient T2 cells. Then, HLA-A’0201 expression levels were measured and compared with those induced by incubation of T2 cells with an irrelevant peptide (Table 1 and Fig. S1). DEPDC1-derived peptides induced different levels of HLA-A’0201 expression, being DEPDC1#1 and DEPDC1#5 those with the highest ability to stabilize the MHC molecule.

\textbf{DEPDC1#5 peptide induces interferon-gamma (IFN\(\gamma\)) production in peptide-stimulated T-cell cultures}

Monocytes were obtained from peripheral blood mononuclear cells (PBMC) of healthy donors, and were induced to differentiate into dendritic cells (DC; data not shown) to act as antigen-presenting cells for T-cell stimulation. The lymphocytes isolated from the PBMC of the same healthy donors were immunomagnetically enriched for CD8\(^+\) T cells (80 ± 1.5% of total lymphocytes), being the remaining contaminant CD4\(^+\) T cell subset only fractional (7.6 ± 5.9%). To induce the expansion of antigen-reactive T-cell populations, CD8\(^+\) T cells were stimulated weekly by autologous DC pulsed with DEPDC1-derived peptides. At the third round of stimulation, T cell cultures were screened for IFN\(\gamma\) production in response to HLA-A’0201-positive lymphoblastoid cells (LCL) pre-loaded with different DEPDC1-derived peptides. The most responsive CD8\(^+\) population was observed after stimulation with the DEPDC1#5 peptide. LCL cells loaded with an irrelevant peptide (HLA-A’0201-restricted Gag-1777-85, SLYNTVATL) or left unpulsed did not induce IFN\(\gamma\) production (Figs. 2 and S2). Taken together, these results led us to focus on and further characterize DEPDC1#5 peptide-stimulated T-cell cultures. After three stimulation rounds the bulk population was essentially composed of CD8\(^+\) T cells (79.4 ± 1.5%; \(n = 24\) donors, Fig. 3A), mainly characterized by an effector memory phenotype (78.48 ± 7% of CCR7\(^-\)/CD45RA\(^+\)); \(n = 11\) donors;
rounds of stimulation. The mean percentage memory (EM) and CD45RA sets decrease in vitro three DEPDC1#5 peptide-stimulated CTL are HLA-A restricted, strictly antigen-specific and recognize an endogenously processed epitope in tumor cells

Antigen specificity of CTLs stimulated with DEPDC1#5 peptide was assessed against the MDA-MB-231 TNBC cell line, which is HLA-A*0201-positive and endogenously expresses DEPDC1 (Fig. 4A). Upon challenge with these cells, a consistent fraction of DEPDC1#5 peptide-induced CTLs was stimulated to produce IFNγ (Fig. 4B). On the other hand, the percentage of cytokine-producing CD8+ CTLs sharply dropped in response to MDA-MB-231 cells either pretreated with the anti-MHC class I W6/32 blocking antibody, or silenced for DEPDC1 expression by a specific short hairpin RNA (shDEPDC1). A control scrambled siRNA (shCTRL) produced no relevant effects on recognition. Additionally, a very limited IFNγ response was observed against the human embryonic kidney 293 cell line, which endogenously expresses DEPDC1 (Fig. 4A) but is devoid of the HLA-A*0201 molecule. Conversely, stable transfection of 293 cells with the HLA-A*0201 allele (Fig. S4) led to a prompt and sustained recognition of target cells, revealed by the increased percentage of IFNγ-producing CD8+ T cells (Fig. 4B).

In support of these data, the cytolytic activity of DEPDC1#5 peptide-stimulated CTLs was assessed in a classical 51Cr-release assay (Figs. 4C and S5A). In particular, CTLs exerted a very limited IFNγ response (Fig. 4B). On the other hand, the percentage of cytokine-producing CD8+ CTLs sharply dropped in response to MDA-MB-231 cells either pretreated with the anti-MHC class I W6/32 blocking antibody, or silenced for DEPDC1 expression by a specific short hairpin RNA (shDEPDC1). A control scrambled siRNA (shCTRL) produced no relevant effects on recognition. Additionally, a very limited IFNγ response was observed against the human embryonic kidney 293 cell line, which endogenously expresses DEPDC1 (Fig. 4A) but is devoid of the HLA-A*0201 molecule. Conversely, stable transfection of 293 cells with the HLA-A*0201 allele (Fig. S4) led to a prompt and sustained recognition of target cells, revealed by the increased percentage of IFNγ-producing CD8+ T cells (Fig. 4B).

In support of these data, the cytolytic activity of DEPDC1#5 peptide-stimulated CTLs was assessed in a classical 51Cr-release assay (Figs. 4C and S5A). In particular, CTLs exerted a high cytotoxicity against MDA-MB-231 cell line (Fig. 4C); such lytic effect was significantly reduced upon DEPDC1 silencing, while silencing with a shCTRL did not affect CTL-dependent cytotoxicity, thus confirming antigen specificity. To further demonstrate that CTL activity was specific for the DEPDC1#5 peptide, MDA-MB-231 cells were pulsed with DEPDC1#5 or Gag-1777-85 peptides, and tested for susceptibility to lysis. In this condition, exogenous peptides bind to HLA-A*0201 and replace the endogenously presented peptides. CTLs exhibited a significantly higher lytic activity against DEPDC1#5-pulsed MDA-MB-231 cells as compared with the same cells pulsed with the irrelevant HLA-A*0201-restricted peptide. As a confirmation of the HLA-A*0201 restriction, incubation of MDA-MB-231 cells with the W6/32 blocking antibody led to a significant reduction of cytotoxicity, an effect that was not observed with the addition of an isotype control antibody. Furthermore, DEPDC1#5 peptide-stimulated CTLs were significantly more cytotoxic against HLA-A*0201 transfected 293 cells, which acquire the ability to present DEPDC1-derived peptides in the context of the HLA-A*0201 molecule, compared with wild type 293 cells that lack the expression of this allele.

The critical aspects of peptide specificity and HLA recognition were further confirmed by assessing the lytic activity of DEPDC1#5 peptide-stimulated CTLs against the NIH 3T3 murine fibroblast cell line, in which neither human DEPDC1 nor HLA-A*0201 are endogenously expressed (data not shown and Fig. S4). CTLs did not disclose any relevant activity against wild type NIH 3T3 cells, but cytotoxicity significantly increased when target cells were simultaneously transfected with HLA-A*0201 (Fig. S4) and pulsed with DEPDC1#5 peptide; HLA-A*0201-transfected NIH 3T3 cells unloaded or pulsed with an irrelevant peptide were essentially not recognized (Fig. 4D).

On the other hand, the capacity of DEPDC1#5-stimulated CTLs to recognize the naturally processed and presented epitope was further validated using as targets additional tumor cell lines of different histotypes, namely A375 (melanoma), HepG2 (hepatocellular carcinoma) and U87MG (glioblastoma). Such
cells turned out to be sensitive to killing (Fig. S5A), as expected from both DEPDC1 (Fig. 1B) and HLA-A*0201 (Fig. S5B) expression, with cell lysis apparently correlating with the expression levels of the HLA-A*0201 molecule.

**DEPDC1#5 peptide-stimulated CTLs restrain tumor growth in vitro**

To investigate the ability to induce long-term effects in vitro, DEPDC1#5 peptide-stimulated CTLs were co-cultured with MDA-MB-231 or NIH 3T3 in an outgrowth assay (Fig. 5). After 4 weeks, both MDA-MB-231 and NIH 3T3 reached the full confluency in the absence of lymphocytes. Conversely, the addition of DEPDC1#5 peptide-stimulated CTLs completely inhibited the growth of MDA-MB-231 cells, even at very low effector/target (E/T) ratios. Control CTLs stimulated with an irrelevant peptide were not able to repress MDA-MB-231 growth, and served as control for antigen specificity (Ctrl-CTL). No effects were observed on NIH 3T3 cell growth.

**Adoptively transferred DEPDC1#5 peptide-stimulated CTLs inhibit breast cancer growth and restrain the metastasis process**

Before proceeding with experiments aimed at assessing the in vivo therapeutic efficacy of anti-DEPDC1 T cells upon adoptive transfer, unrelated control effectors were generated. Thus, CTL populations directed against the HLA-A2-restricted Melan-A26–35/C3A27L peptide, which was derived from the melanocyte lineage-specific Melan-A protein expressed in most of primary and metastatic melanomas,39 were obtained following the same protocol used to generate DEPDC1#5 peptide-stimulated CTLs. The amount of CD8+ T cells expressing a Melan-A26–35/C3A27L/HLA-A*0201-specific TCR was quantified using tetramer staining throughout the culture period (25.7 ± 19.44% at the third round of stimulation, n = 3 healthy donors) (Fig. S6A and B). The cytotoxic activity of Melan-A26–35/C3A27L peptide-stimulated CTLs was assessed in a classical 51Cr-release assay to confirm that they did not recognize MDA-MB-231 cells alone or pre-loaded with the DEPDC1#5 peptide (Fig. S6C). Conversely, when breast cancer cells were pulsed with the Melan-A26–35/C3A27L peptide, the cytotoxicity was significantly increased.

Thereafter, the in vivo therapeutic efficacy of DEPDC1#5 peptide-stimulated and control CTLs was evaluated against MDA-MB-231 cells stably transduced with the firefly luciferase (luc) reporter gene, and injected into the mammary fat pad of NOD/SCID common γ chain knockout (NSG) female mice. Three days after inoculation, the tumor was detected by bioluminescence (BLI), and a group of mice (n = 9) received intratumor injections of DEPDC1#5 peptide-stimulated CTLs for a total of three doses, whereas another group (n = 8) received...
CTL cultures stimulated against the irrelevant Melan-A26–35/A27L peptide; the untreated mice (n = 18) were injected with PBS (Fig. 6A). While a progressive increase in tumor growth was observed in the two groups of control mice, DEPDC1#5 peptide-stimulated CTL treatment was able to delay the growth of primary tumor (Fig. 6B). When MDA-MB-231 cells are injected orthotopically, metastases are frequently observed 3–4 weeks later in the axillary lymph nodes and lungs.40-42 In this regard, mice treated with DEPDC1#5 peptide-stimulated CTLs showed a significant reduction in peripheral metastatic colonization as compared with untreated mice and to mice treated with Melan-A-specific CTLs, when examined at the same primary tumor size (Fig. 6C), thus clearly indicating that DEPDC1#5 peptide-stimulated CTLs were also effective in inhibiting metastases.

Discussion

Tumor-specific mutations can be envisaged as ideal targets for cancer immunotherapy since they are not present in healthy tissues and can potentially be recognized as neoantigens by the T-cell repertoire. However, mutated protein-based personalized vaccines are hampered by the fact that in each patient the tumor possesses a unique set of mutations, which must be first identified with enormous time-consuming and expensive molecular screenings. Therefore, the identification of TSA shared by multiple patients and different types of cancers is likely destined to become again crucial for overcoming these problems and making immunotherapy universally applicable.

The involvement of DEPDC1 in many cancer traits suggests its key role in tumor cell growth and survival,13,43 hence supporting a low possibility of antigen downregulation. Therefore, we investigated DEPDC1 gene expression among human cancer tissues using the Oncomine database, and found that it is overexpressed almost ubiquitously in human cancers as compared with healthy counterpart tissues. This aspect, together with its involvement in the oncogenic process, strongly indicates that DEPDC1 can be regarded as a novel universal oncoantigen, potentially suitable for targeting many different tumors. Additionally, the pathologic and prognostic value of DEPDC1 upregulation is consistently supported by its association with the most common clinic-pathological variables associated to cancer aggressiveness, such as the presence of regional nodal metastasis, invasion of distant organs and presence of poorly differentiated or undifferentiated abnormal-looking cells, and a significant correlation was demonstrated with both overall and disease-free survival. According to the predominant DEPDC1 overexpression in most aggressive tumors, its upregulation was found to be particularly relevant in TNBCs, which are characterized by a poorer prognosis respect other forms of breast cancer, and associated with an increased risk of recurrence within 3 y from diagnosis and an increased 5-y mortality rate.23 In this regard, our study shows that the identified HLA-A*0201-restricted DEPDC1-derived peptide could be exploited for immunotherapy against TNBCs, which unfortunately still suffer from the lack of therapeutic options already available for other breast cancer subtypes.44

We decided to focus on the HLA-A*0201 allele as it is the most common HLA class I subtype in the Caucasian population and the second most common in the Japanese population.45,46 Therefore, 10 HLA-A*0201-restricted DEPDC1-derived peptides were identified by integrating the results of three epitope prediction programs based on the prediction of peptide binding affinity to MHC, on the probability of peptide proteasomal cleavage and on the efficiency of peptide transport trough the endoplasmic reticulum. One of the peptides tested had the ability to induce a specific and relevant functional CTL
response against target cells; indeed, DEPDC1#5-stimulated CTLs produced IFN-γ in presence of both target cells artificially loaded with the DEPDC1#5 peptide, and tumor cells endogenously expressing the DEPDC1 protein. Furthermore, despite the small percentage of tetramer-positive T cells, the DEPDC1#5-stimulated CTL populations exerted a relevant and specific cytotoxic activity against TNBC cells, indicating that they naturally process the DEPDC1 antigen and present the epitope in association with the HLA-A*0201 molecules, thus becoming susceptible to the CTL attack. These findings suggest that even a small fraction of antigen-specific T cells can exert a significant lytic function, likely due to the recycling potentialities of the effectors, ultimately leading to a marked enhancement of the overall activity of DEPDC1#5-specific lymphocytes. Apparently, the functional response mediated by DEPDC1#5-stimulated CTLs was not a short-term effect, as completely inhibited in vitro breast cancer cell growth even at very low E/T ratios. Moreover, in a TNBC mouse model DEPDC1-stimulated CTL delayed breast tumor growth and reduced peripheral colonization despite the apparently limited number of DEPDC1#5-specific CD8+ T cells injected, thus demonstrating the effectiveness of the CTL therapy also in

---

**Figure 6.** Assessment of therapeutic efficacy in vivo of DEPDC1#5 peptide-stimulated CTL. (A) On day 0, NSG mice were injected into the mammary fat pad with 1 × 10⁶ luc-transduced MDA-MB-231 cells, and were treated intra-tumorally at days 3, 6 and 10 with 1 × 10⁷ DEPDC1#5 peptide-stimulated CTLs (n = 9) or Melan-A peptide-stimulated CTL (n = 8). The untreated group of mice received three injections of PBS1X (n = 18). (B) Tumor growth was monitored by BLI measurement as photon flux. Left panels show the primary tumor BLI of three representative mice for each group after 29 d from tumor injection, while right panel reports tumor growth of all animals at different time points (mean of photons/second ± SD: ***p < 0.001; the ANOVA was used for statistical analysis). (C) Distant metastatic colonization was evaluated by BLI when a primary tumor size of about 700 mm³ was reached in each group. The left panels show the BLI of distant metastases in three representative mice for each group, while right panel reports the photons/second detected in each individual mouse belonging to the different groups (*p < 0.05; **p < 0.01).
restraining the metastasis process. Conversely, CTL populations directed against the well-known immunogenic Melan-A protein, which is not expressed in MDA-MB-231 cells, had no therapeutic effects despite the higher amount of Melan-A.

The limited number of DEPDC1-specific T cells obtained after *in vitro* stimulations could represent a potential limitation for ACT. Nonetheless, it must be considered that our DEPDC1-specific CTL cultures were generated from PBMC of healthy donors, where the precursor frequency is almost undetectable, while priming of DEPDC1-specific T cells could occur in tumor patients. In this regard, a preliminary survey on a very limited number of TNBC patients provided evidence of a potential response in one patient, thus suggesting the need of further studies. Alternatively, a higher number of DEPDC1-specific T cells could be obtained by stimulating cultures with a Rapid Expansion Protocol, or with cellular or acellular artificial Antigen Presenting Cells (aAPC), even though these protocols generate a large number of non-specific responders, the interactions between T cells and aAPC are weaker than those between the lymphocytes and the natural autologous APC.

Taking together, the results of this study emphasize the idea that DEPDC1 can be considered as a universal tumor antigen, and might represent a potential and safe target for cancer immunotherapy, as its overexpression is confined only in tumor cells and not in normal tissues. In support of this concept, results of three vaccination clinical studies based on a HLA-A24-restricted DEPDC1-derived peptide have shown a good tolerability and provision of clinical benefit to patients with both bladder cancer and other different solid tumors.

**Materials and methods**

**cDNA microarrays analysis**

The Oncomine database, a repository for published cancer-profiling cDNA microarray data, was explored for DEPDC1 mRNA expression in various human tumor tissues, and in the corresponding non-neoplastic tissues. Statistical analysis of the differences in DEPDC1 expression was accomplished through the use of the ONCOMINE algorithms, which allow multiple comparisons among different studies. The fold change and gene rank were determined with results achieving a *p* < 0.05 were considered.

**Western blot**

Total cell extracts from tumor cells were obtained with a buffer containing 50-mM Tris–HCl pH 7.5, 2-mM EDTA, 150-mM NaCl, 1% NP-40 and 1% protease inhibitor cocktail (Roche Biochemical Reagents). Protein concentration was determined by BCA Protein Assay Micro Kit (Serva Electrophoresis). Lysates were resolved by SDS-sample buffer (4% sodium dodecyl sulfate (SDS), 200-mM Tris–HCl pH 6.8, 3% β-Mercaptoethanol, 6% glycerol and 0.6% Bromphenol Blue, all from Sigma-Aldrich), boiled for 5 min before loading in NuPage Novex 4–12% Bis-Tris Midi Protein gels (Invitrogen), and then transferred to the nitrocellulose membrane (PerkinElmer). DEPDC1 expression was assessed in non-neoplastic samples using a commercially available tissue microarray (ProSci) containing nine normal human tissues (bladder, breast, cervix, kidney, ovary, placenta, prostate, testis and uterus). Western blot analysis was performed according to standard procedures using a rabbit anti-DEPDC1 polyclonal antibody (1:500, Abcam) and HRP-conjugated goat anti-rabbit IgG (diluted 1:3,000, Abcam) secondary antibody. The membrane was developed with ECL detection reagents (ThermoFisher Scientific) and visualized using chemiluminescence. Signal intensity was measured by a Bio-Rad XRS chemiluminescence detection system (Lyfe Science Group).

**Cell lines**

The following cell lines were used in this study: the human TNBC cell line MDA-MB-231 (HLA-A*0201*), and the related derivatives MDA-MB-231 shDEPDC1 and MDA-MB-231 shCTRL that have been stably transduced with a short hairpin RNA (siRNA) for DEPDC1 silencing or with a control siRNA, respectively; the human TNBC cell line MDA-MB-468; MCF-7, a human breast cancer cell line; the human bladder cancer cell line SW-780; U87MG, a human glioblastoma cell line; HeLa, a human cervix adenocarcinoma cell line; HCT-15, a human colorectal adenocarcinoma cell line; MKN-45, a human gastric cancer cell line; K562, a human chronic myelogenous leukemia cell line; HepG2, a human hepatocellular carcinoma cell line; A549, a human lung carcinoma cell line; A375, a human melanoma cell line; the human embryonic kidney cell line 293 (HLA-A*0201*) and 293-A2 (stably expressing the HLA-A*0201* molecule upon pcDNA3/neoplasmid-mediated transfection using Lipofectamine2000 (Invitrogen)); the T2 cells (HLA-A*0201*), a TAP-deficient human hybrid B/T lymphoblastic cell line; the mouse fibroblast cell line NIH 3T3 and NIH 3T3-A2 (stably expressing HLA-A*0201* upon retroviral transduction). Cells were maintained in DMEM (MDA-MB-231, MDA-MB-468, MCF-7, SW-780, U87MG, HeLa, HepG2, A549, A375, 293 and NIH 3T3) or RPMI 1640 (HCT-15, MKN-45, K562, T2) medium (EuroClone) supplemented with 10% Fetal Bovine Serum (FBS, Gibco), 2 mM L-Glutamine, 10 mM HEPES, 100-U/mL Penicillin and 100 U/mL Streptomycin (all from Lonza), at 37 °C in a 5% CO₂ atmosphere.

**Peptide selection and synthesis**

Several 9-mer HLA-A*0201* binding motifs from DEPDC1 protein sequence were selected based on an integration of their score using the HLA peptide binding prediction algorithms available at BIMAS (http://www-bimas.cit.nih.gov/molbio/hla_bind/), NetMHC (http://www.cbs.dtu.dk/services/NetMHC/) and NetCTL (www.cbs.dtu.dk/services/NetCTL/) websites. A total of 10 HLA-A*0201* restricted peptides were chosen. The DEPDC1-derived HLA-A*2402*-restricted peptide EYYELFVNI served as negative control in the T2 stabilization assays. All peptides were synthesized by CRIBI (Padova, Italy) with a purity of 98% verified by mass spectrometry analysis. The peptide SLYNTVATL (HIV-1 p17 Gag, aa 77–85; named
Gag-1777–85 was used as negative control in functional assays, as it was described previously as an optimal HLA-A2-restricted CTL epitope. The HLA-A2-restricted peptide ELAGIGILT (Melan-A/MART-1 analog, aa 26–35) was named Melan-A26–35/A2TL; named Melan-A26–35/A2TL was used for the selection and expansion of Melan-A-specific T cells for in vivo experiments.

**T2 stabilization assay**

Binding and stabilization of HLA-A*0201 molecule by DEPDC1-derived peptides was evaluated using T2 cells. T2 cells were stripped in 0.131 M citric acid, 0.066 M Na2HPO4 (pH 3.3) for 45 s, washed and resuspended in serum-free culture media. A total of 2 × 10^5 cells were incubated with 3 μg/ml β2-microglobulin (Sigma-Aldrich) and 100 μg/ml peptide in a final volume of 500 μL for 4 h at 37 °C. Cells were then washed and stained with the FITC-conjugated HLA-A*0201 monoclonal antibody BB7.2 (BioLegend) before cytometry evaluation (FACSCalibur, BD Biosciences). Stabilization was calculated by dividing the Mean Fluorescence Intensity (MFI) of peptide-pulsed T2 cells with the MFI of T2 cells loaded with a negative control peptide (EYYELFVNI) with no predicted binding affinity to HLA-A*0201.

**Generation of peptide-specific T cells from healthy donors**

CD8^+ T cells and monocyte-derived DCs were obtained from peripheral blood of HLA-A*0201 positive healthy donors. PBMC were isolated by Ficoll-Plaque PLUS (GE Healthcare) density gradient centrifugation, and then separated by adherence to plastic culture flasks (Falcon) for 1.5 h at 37 °C in 5% CO2 to enrich the monocyte fraction. Non-adherent cells were collected and purified for CD8^+ T cells using MACS CD8^+ microbeads (Miltenyi Biotec) according to manufacturer’s instructions. Isolated CD8^+ T cells were cryopreserved until further use. The adherent fraction was differentiated into mature DC by culture in RPMI 1640 supplemented with 8% Human AB serum (HS; Aurogene), 2 mM L-Glutamine, 10 mM HEPES, 100 U/mL Penicillin, 100 U/mL Streptomycin and 50 μM 2β-mercaptoethanol for 7 d with the addition of 1,000 U/mL granulocyte-macrophage colony-stimulating factor (GM-CSF) and 500 U/mL IL-4 (PeproTech). After 5 d, 1 μg/mL of LPS was added, and the DCs’ mature phenotype at day 7 was confirmed by flow cytometry analysis of the expression of CD14 (clone TUK4; Miltenyi), CD83 (clone HB15; Miltenyi), CD86 (clone FM95; Miltenyi), CD80 (clone L307.4; BD Biosciences), CCR7 (clone G043H7; BioLegend), HLA-ABC (clone W6/32; BioLegend) and HLA-DR (clone L243; BioLegend) markers. Mature DCs were pulsed with 20 μg/mL of synthesized peptides in presence of 3 μg/mL β2-microglobulin (Sigma) in RPMI 1640 medium supplemented with 3% HS at 37 °C for 4 h. These peptide-pulsed DC were then irradiated (35 Gy) and mixed at 1:10 ratio with autologous CD8^+ T cells in a complete medium supplemented with 8% HS, 10 ng/mL IL-7 (PeproTech) and 20 U/mL rhIL-2 (Prolleukine, Novartis). After 2 d, half of medium was replaced with fresh medium supplemented with 100 U/mL rhIL-2. On days 7, 14 and 21, T cells were restimulated with the autologous peptide-pulsed DC as described above.

**Intracellular cytokine staining for IFNγ detection**

IFNγ production in response to peptide epitopes was measured by intracellular cytokine staining after blocking the cellular secretion using BD Cytofix/Cytoperm kit, according to the manufacturer’s instructions. HLA-A*0201-positive LCL or tumor target cell lines were used as stimulators. LCL cells were pulsed overnight with each peptide (10 μg/mL), washed and incubated at 1:1 ratio with peptide-specific CTLs stimulated three times with autologous peptide-pulsed DC. The Gag-177-85 peptide served as negative control, while phorbol 12-myristate 13-acetate (PMA; 40 ng/mL)/ionomycin (4 μg/mL) (Sigma Aldrich) as positive control. After 1 h, cellular cytokine secretion was blocked by the addition of GolgiStop (2 μM) and the incubation was allowed to continue for 5 h at 37 °C. Cells were then stained with APC-conjugated anti-CD8α antibody (clone RPA-T8; BioLegend), washed and fixed. After permeabilization, cells were stained with a PE-conjugated anti-IFNγ antibody (clone B27; BioLegend) for 30 min at 4 °C, and flow cytometry analysis was performed (FACSCalibur, BD Biosciences).

**MHC-biomonomer and MHC-tetramer preparation**

The synthesis of MHC-peptide tetrameric complexes has been reported previously. Briefly, the MHC HLA-A*0201 heavy chain, β2m and epitope peptide (DEPDC1#5 or Melan-A26–35/A2TL peptides) were subjected to a refolding in vitro in Tris–HCl pH 8, L-Arginine-HCl, NaEDTA, oxidized glutathione and reduced glutathione (Sigma-Aldrich). The complex was isolated through dialysis, concentrated and purified by HPLC to separate monomers from unconjugated components. Monomers were then enzymatically biotinylated by the enzyme BirA. The biomonomers obtained were purified and then quantified with a spectrophotometer. The tetramers were finally assembled with PE-conjugated extravidin (Sigma-Aldrich) for subsequent use in flow cytometry analysis.

**Peptide-stimulated T-cell characterization**

T cells selected and expanded in vitro were characterized using the following fluorochrome-conjugated monoclonal antibodies: APC-conjugated CD3 (clone UCHT1; BioLegend) and CD8^+ (clone RPA-T8; BioLegend); FITC-conjugated CD16 (clone 3G8; BioLegend) and CCR7 (clone G043H7; BioLegend); PerCP-Cy5.5-conjugated CD56 (clone B159; BD Biosciences) and CD45RA (clone HI100; BioLegend); BV421-conjugated CD8^+ (clone RPA-T8; BD Biosciences); APC-H7-conjugated CD4^+ (clone RPA-T4; BD Biosciences); PE-conjugated CD4^+ (clone RPA-T4; BioLegend). For the tetramer staining, CTLs were incubated with the PE-conjugated HLA-A*0201-DEPDC1#5 or PE-conjugated HLA-A*0201-Melan-A26–35/A2TL tetramers. Samples were analyzed by an LSRII flow cytometer (BD Biosciences) and evaluated with FlowJo software (TreeStar, Inc.).

**51Cr-release assay**

DEPDC1#5 peptide-specific CTL cytotoxic activity was assessed using a 6 h 51Cr-release assay. Briefly, a total of 1 ×
10⁶ target cells were labeled with 100 μCi of Na₂⁵¹CrO₄ for 1 h at 37 °C and washed twice with culture medium. Depending on the experiment, target cells were incubated with 10 μM of DEPDC1#5, Gag-177-85 or Melan-A26-35/35/27L peptides for 40 min at 37 °C and then washed twice. For blocking experiments, target cells were incubated for 30 min on ice with 10 μg/ml anti-MHC-class I blocking antibody (W6/32 clone; BioLegend) or the relative isotype control (mouse IgG2a, κ isotype ctrl; BioLegend). Target and effector cells were then plated in a 96-well U-bottom plate at the indicated E/T ratio in a total volume of 200 μL. After 6 h of incubation at 37 °C, 30 μL supernatant was transferred on a scintillation plate (PerkinElmer), and measured using a Top Count gamma counter (PerkinElmer). The percentage of lysis was calculated as follows: % Specific lysis = (experimental release – spontaneous release)/(maximal release – spontaneous release) × 100. Spontaneous and maximal releases were obtained by incubating target cells in medium alone or in RPMI 2% SDS, respectively. Cytotoxicity was expressed as lytic units 30 (LU30) or lytic units 20 (LU20), where 1 LU30 or 1 LU20 were defined as the number of effector cells capable of killing 30% or 20% of target cells, respectively. Results were expressed in number of LU30 or LU20 per 10⁶ responder cells.

**Outgrowth assays**

Target MDA-MB-231 or NIH 3T3 cells were serially double diluted into replicate flat-bottom 96-wells plate starting from 3,000 cells/well, and T cells were added where indicated at 3,000 cells/well. Plates were incubated at 37 °C in 5% CO₂ with weekly refeeding, and target cells outgrowth was scored after 4 weeks.

**In vivo experiments of adoptive immunotherapy**

On day 0, 6–8 weeks old female NSG (Charles River) mice were anesthetized (1–3% isoflurane, Merial Italia), and injected into the mammary fat pad with 1 × 10⁶ MDA-MB-231 cells transduced with a lentiviral vector coding for the Firefly Luciferase reporter gene. At day 3, mice were injected intra-tumorally with 10 × 10⁶ DEPDC1-specific or Melan-A-specific CTL stimulated three times with autologous peptide-pulsed DC. Another group of mice received only PBS1X as negative controls. The same treatment was repeated for two additional times at 3–4 d interval.

Tumor growth was monitored over time by bioluminescence analysis. In particular, anesthetized animals were given the substrate D-Luciferin (PerkinElmer) by intraperitoneal injection at 150 mg/kg in PBS (Sigma). The light emitted from the bioluminescent tumors or metastasis was detected using a cooled charge-coupled device camera mounted on a light-tight specimen box (IVIS Lumina II Imaging System; PerkinElmer). Imaging times ranged from 15 s to 8 min. Regions of interest from displayed images were identified around the tumor sites or at peripheral metastasis region, and were quantified as total photon counts or photon/s using Living Image® software (PerkinElmer). For the peripheral metastatic colonization detection, the lower portion of each animal was shielded before imaging to minimize the bioluminescence from primary tumor, thus allowing the signals from metastatic regions to be observed in vivo.

**Statistical analysis**

Results were analyzed for statistical significance by using paired or unpaired Student’s t-test and ANOVA, as appropriate (***p < 0.0001; **p < 0.001; *p < 0.01; *p < 0.05). Histograms represent mean values ± SD. In scatter-plot graphs, symbols indicate different samples or assays, and horizontal bars represent means ± SD. Statistical analysis was performed using SigmaPlot and GraphPad Prism 4.0 software.

**Study approval**

Anonymized human buffy coats were obtained from the Blood Bank of Padova Hospital, and donors provided their written informed consent to participate in this study. Procedures involving animals and their care were in conformity with institutional guidelines that comply with national and international laws and policies (D.L. 26/2014 and subsequent implementing circulars), and the experimental protocol (Authorization no. 1143/2015-PR) was approved by the Italian Ministry of Health.

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.

**Acknowledgment**

We thank A. Testa for reading the manuscript and for discussions.

**Funding**

This work was partly supported by grants from the Italian Association for Cancer Research (AIRC, IG-17035) to A. R., AIRC Special Program Molecular Clinical Oncology “5 per mille” (ID 10016) to A. R. and G. D. S., and Progetto di Ricerca di Ateneo 2015, University of Padova, to A. R. We acknowledge the support by the Italian Ministry of Health (RF-2011-02346976), the Italian Ministry of University and Research (PRIN-2015-8KZ KE3), Cariplo Foundation (Grant no. 2014-0812), and Beneficenza-Stiftung, to G. D. S.

**ORCID**

Silvia Dalla Santa http://orcid.org/0000-0002-5616-6494
Paola Zanovello http://orcid.org/0000-0003-0740-4043
Roberta Sommaggio http://orcid.org/0000-0002-5682-5867
Antonio Rosato http://orcid.org/0000-0002-5263-8386

**References**

1. Neves H, Kwok HF. Recent advances in the field of anti-cancer immunotherapy. BBA Clin 2015; 3:280-8; PMID:26673349; https://doi.org/10.1016/j.bbacli.2015.04.001
2. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015; 14(8):561-84; PMID:26228759; https://doi.org/10.1038/nrd4591
3. Taube JM, Klein A, Brahamer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014; 20(19):5064-74; PMID:24714771; https://doi.org/10.1158/1078-0432.CCR-13-3271
4. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small
cell lung cancer. Science 2015; 348(6230):124-8; PMID:25765070; https://doi.org/10.1126/science.aaa1348

5. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Haley CT et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016; 351(6280):1463-9; PMID:26806566; https://doi.org/10.1126/science.aaf1490

6. Melero I, Berman DM, Aman MA, Korman AJ, Pinto SM, Kinchen JM, Shi M et al. DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis. Nat Cell Biol 2014; 16(8):812-20; PMID:25064737; https://doi.org/10.1038/ncb3010

7. Chung S, Kijima K, Kudo A, Fujisawa Y, Harada Y, Taira A, Taka-matsu N, Miyamoto T, Matsuo Y, Nakamura Y. Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor. Cancer Res 2017; 78(16):4324-35; https://doi.org/10.1158/0008-5472.CAN-16-3031

8. Geynisman DM, Chien C-R, Smieliauskas F, Shen C, Shih Y-CT. Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review. Hum Vaccin Immunother 2014; 10(11):3413-24; PMID:25498356; https://doi.org/10.1089/hvi.2014.0297

9. Couli PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014; 14(2):135-46; PMID:24457417; https://doi.org/10.1038/nrc3670

10. Chappuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, Duerkopp N, Roberts IM, Pogosov GL, Ho WY et al. Transferred WT1-reactive CD8+ T cells can mediate anti-leukemic activity and persist in post-transplant patients. Sci Transl Med 2013; 5(174):174ra27; PMID:23447018; https://doi.org/10.1126/scitranslmed.3004916

11. Wright SE, Rewers-Felkins KA, Quinlin IS, Phillips CA, Townsend M, Reddinger MD, Wang Z, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Berman DM, Aznar MA, Korman AJ. DEPDC1 is a novel cell cycle related gene that regulates mitotic progression. BMB Rep 2015; 48(7):413-18; PMID:25902835; https://doi.org/10.4583/BMBRep.2015.48.7.036

12. Girardin JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci M, Errico M, de Rinaldis E, Blasi MF, Viti V, Falchetti M, Calcagnile A, Sera F, Saieva C, Ottini L, Palli D et al. Global gene expression profiling and validation in esophageal squamous cell carcinoma identifies HOXC10 as a key mediator of tumour progression. J Clin Oncol 2010; 28(16):2660-7; PMID:20421545; https://doi.org/10.1158/1053-817X.JCO.2009.25.0977

13. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribout N, Regli L, Wick W, Kouwenhoven MC et al. Stem cell-related "self-renewal" signature and high epithelial growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008; 26(18):3015-24; PMID:18565887; https://doi.org/10.1200/JCO.2007.15.7164

14. Zhai Y, Kuick R, Nan B, Ota I, Weiss SJ, Trimble CL, Fearon ER, Cho KR. Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion. Cancer Res 2007; 67(21):10163-72; PMID:17974957; https://doi.org/10.1158/0008-5472.CAN-07-2056

15. Skrzypczak M, Goryca K, Rubel T, Paziewska A, Mikula M, Jarosz D, Pachlewski J, Olejdzik J, Ostrowski J. Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data directed for maximization of analytical reliability. PLoS One 2010; 5(10):e13091; PMID:20957034; https://doi.org/10.1371/journal.pone.0013091

16. Su H, Hu N, Yang HH, Wang C, Takikita M, Wang QH, Giffen C, Clifford R, Hewitt SM, Shou JZ et al. Global gene expression profiling and validation in esophageal squamous cell carcinoma and its association with clinical phenotypes. Clin Cancer Res 2011; 17(9):2955-66; PMID:21385931; https://doi.org/10.1158/1078-0432.CCR-10-2724

17. D’Errico M, de Rinaldis E, Blasi MF, Viti V, Falchetti M, Calcagnile A, Sera F, Saieva C, Ottini L, Palli D et al. Genome-wide expression...
 profile of sporadic gastric cancers with microsatellite instability. Eur J Cancer 2009; 45(3):461-9; PMID:19081245; https://doi.org/10.1016/j.ejca.2008.10.032

33. Sengupta S, den Boon JA, Chen I-H, Newton MA, Dahl DB, Chen M, Cheng YJ, Westra WH, Chen CJ, Hildesheim A et al. A genomic analysis of adult T-cell leukemia. Oncogene 2007; 26(8):1245-55; PMID:16909099; https://doi.org/10.1038/sj.onc.1209899

34. Wurmback E, Chen Y, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Brux J et al. Gene-expression-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007; 45(4):938-47; PMID:17393520; https://doi.org/10.1002/hep.21622

35. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC et al. Gene expression-based classification of non-small cell lung carcinoma and survival prediction. PLoS One 2010; 5(4):e10312; PMID:20421987; https://doi.org/10.1371/journal.pone.0010312

36. Riker AL, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 2008; 1;13; PMID:18442402; https://doi.org/10.1186/1755-8799-1-13

37. Christensen O, Lupu A, Schmidt M, belle S, maier A, Hose D, Neuber B, Moos M, Kleist C et al. Melan-A/MART1 antigen triggers anti-meloma T-cells through crossreactivity with HM1.24. J Immunother 2009; 32(6):621-3; PMID:19483648; https://doi.org/10.1097/JIT.0b0131818159198

38. Jorns E, Drews-Elger K, Ward TM, Dean S, Clarke J, Berry D, El Ashfy D, Lippman M. A new mouse model for the study of human breast cancer metastasis. PLoS One 2012; 7(10):e47995; PMID:23181988; https://doi.org/10.1371/journal.pone.0047995

39. Di Minin G, Bellazzo A, Dal Ferro M, Chiarotti G, Nuzzo S, Bicciato S, Piazza S, Raimondo A, Bulla R, Sommaggio R et al. Mutant T3 prograns TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Mol Cell 2014; 54(5):617-29; PMID:16909099; https://doi.org/10.1038/sj.onc.1209898

40. Rustighi A, Zannini A, Tiberi L, Sommaggio R, Piazza S, Sorrentino G, Nuzzo S, Tuscano A, Eterno V, Benvenuti F et al. Prolyl-isomerase PPI1 controls normal and cancer stem cells of the breast. EMBO Mol Med 2014; 6(9):99-119; PMID:24253760; https://doi.org/10.1002/emmm.201302909

41. Kassambara A, Schoenhals M, Moreaux J, Veyrunle JL, Remé T, Goldschmidt H, Hess D, Klein B. Inhibition of DEPDC1A, a bad prognostic marker in the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. J Infect Dis 1996; 173(2):476-9; PMID:8568316; https://doi.org/10.1093/infdis/173.2.476

42. Nijman HW, Houbiers JG, Driehout JW, D’Amaro J, Kenemans P, Melief CJ, Kast WM. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1. J Exp Med 1994; 180(4):1283-93; PMID:75253570; https://doi.org/10.1084/jem.180.4.1283

43. Harrer E, Harrer T, Barbosa F, Feinberg M, Johnson RP, Buchbinder S, Walker BD. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. J Infect Dis 1996; 173(2):476-9; PMID:8568316; https://doi.org/10.1093/infdis/173.2.476

44. Mansour C, Hofmann K, Kastelein R, Molenkamp L, van der Pas M, Nabbe M, van den Berg B, de Jong P, van der Velden F et al. Dynamic bioluminescence imaging for quantitative tumour burden and lymph node assessment using IV or IP administration of D: -luciferin: effect on the progression of the systemic disease and the intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging 2008; 35(5):999-1007; PMID:18180921; https://doi.org/10.1007/s00259-007-0664-2